Divisions of Adult Hematology and SCT, Department of Oncology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Kingdom of Saudi Arabia; King Abdullah International Medical Research Center (KAIMRC), Riyadh, Kingdom of Saudi Arabia; King Saud bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia.
King Saud bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia; Department of Biostatistics and Bioinformatics, King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia.
J Infect Public Health. 2021 Mar;14(3):353-357. doi: 10.1016/j.jiph.2020.12.015. Epub 2020 Dec 30.
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is associated with a high fatality rate (34%), which is higher in the presence of co-morbidities. The aim of the current study was to assess the clinical course and the outcome in hematological or oncological malignancy cases, diagnosed with MERS-CoV.
This is a case series of hematological /oncological cases, diagnosed with MERS-CoV, in a tertiary care setting in 2015. The cases were identified based on the World Health Organization (WHO) MERS-CoV case definition. The demographic, clinical, and outcome data were retrieved from the patients' medical charts and electronic health records.
In total, nine hematological or oncological cases were identified, diagnosed with MERS-CoV. The baseline malignant condition was hematological malignancy in seven patients, as well as colon cancer and osteosarcoma in one patient each. Six (67%) patients were male. The median age was 65 years (range 16-80 years). Co-morbidities included chronic kidney disease (n = 3.33%), diabetes mellitus (n = 3.33%), and hypertension (n = 2.22%). The presenting symptoms were shortness of breath (n = 6.66%), fever (n = 5.55%), cough (n = 2.22%), and diarrhea (n = 2.22%). Chest x-rays indicated bilateral infiltrates in 6 patients (66%). The PCR (polymerase chain reaction) test was repeated in six patients to confirm the diagnosis. The mortality rate was 100%, and the median time to death was 26 days (range 15-77 days).
MERS-CoV infection in this small cohort of hematology or oncology patients has a 100% mortality rate, regardless of the status of the underlying disease. The confirmation of the diagnosis may require repeated testing. Additional studies are required to verify the findings and to elucidate the disease pathogenesis in cancer patients.
中东呼吸综合征冠状病毒（MERS-CoV）死亡率较高（34%），在合并症的情况下更高。本研究的目的是评估 2015 年在三级护理环境中诊断为 MERS-CoV 的血液系统或恶性肿瘤病例的临床过程和结局。
这是在 2015 年在三级护理环境中诊断为 MERS-CoV 的血液系统/恶性肿瘤病例的病例系列。根据世界卫生组织（WHO）MERS-CoV 病例定义确定病例。从患者的病历和电子健康记录中检索人口统计学、临床和结局数据。
共确定了 9 例血液系统或恶性肿瘤病例，诊断为 MERS-CoV。7 例患者的基线恶性疾病为血液系统恶性肿瘤，1 例患者分别为结肠癌和骨肉瘤。6 例（67%）患者为男性。中位年龄为 65 岁（范围 16-80 岁）。合并症包括慢性肾脏病（n=3.33%）、糖尿病（n=3.33%）和高血压（n=2.22%）。首发症状为呼吸急促（n=6.66%）、发热（n=5.55%）、咳嗽（n=2.22%）和腹泻（n=2.22%）。6 例患者的胸部 X 线显示双侧浸润（66%）。重复进行了 6 例患者的 PCR（聚合酶链反应）检测以确认诊断。死亡率为 100%，中位死亡时间为 26 天（范围 15-77 天）。
在本血液学或肿瘤学患者小队列中，MERS-CoV 感染的死亡率为 100%，与基础疾病的状态无关。可能需要重复检测来确认诊断。需要进一步研究来验证这些发现，并阐明癌症患者的疾病发病机制。
